Page 1

August 23 , 2021 KHIRON LIFE SCIENCES CORP Khiron Reports Q2 Results , 47 % QOQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany • Q2 2021 revenues of $ 2.8 million , up 68 % YoY • Medical cannabis revenues reach $ 825,500 , up 47 % sequentially , with sales in Colombia , Germany , UK , and Peru contributing to gross medical cannabis profit margin of 88 % • European medical cannabis sales growth of 280 % sequentially , representing over 25 % of total medical cannabis revenues • Medical cannabis expected to become dominant revenue stream , with monthly revenues forecast to increase to over $ 1 million by Q1 2022 , on top of expected $ 1 million in health services • $ 9.4 million in cash as of June 30,2021 , a decrease of $ 3.2 million from march 3 t 2021 , and proforma Q2 2021 cash balance of $ 20.6 million , including estimated net proceeds from the Company's July 2021 offering TORONTO , Aug. 23 , 2021 / CNW / - Khiron Life Sciences Corp. ( " Khiron " or the " Company " ) ( TSXV : KHRN ) ( OTCQX : KHRNF ) ( Frankfurt : A2JMZC ) , a vertically integrated cannabis leader with core operations in Latin America and Europe , today announces its financial results for the quarter ended June 30 , 2021. These filings are available for review on the Company's SEDAR profile at www.sedar.com . All financial information in this press release is reported in Canadian dollars , unless otherwise indicated .